개인구독
소속 기관이 없으신 경우, 개인 정기구독을 하시면 저렴하게
논문을 무제한 열람 이용할 수 있어요.
지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
논문 기본 정보
- 자료유형
- 학술저널
- 저자정보
- 발행연도
- 2015.1
- 수록면
- 4 - 21 (18page)
이용수
초록· 키워드
오류제보하기
Osteoporosis is characterized by low bone mass, deteriorated bone architecture and increased risk of is fractures. The current available treatments of osteoporosis comprise antiresorptive and anabolic treatments. Bisphosphonates and RANKL antibody are the most widely used antiresorptive treatments while teriparatide is the only available anabolic treatment of osteoporosis. A common feature of antiresorptive as well as anabolic treatment is that bone resorption and formation remain coupled. Both types of treatment therefore establish a period of positive balance but because of the coupling, this period is temporary. The focus of this review is two new classes of anti-osteoporosis treatments; inhibition of cathepsin K and inhibition of sclerostin. Through very different mechanisms of action both may prove capable of uncoupling resorption and formation. Cathepsin K is a lysosomal cysteine protease that degrades bone matrix proteins including collagen type I. Animal and human studies have demonstrated that inhibition of cathepsin K leads to increased bone mass across species and reduced fracture risk in postmenopausal women. Sclerostin activates the Wnt canonical pathway and stimulates bone formation through stimulation of osteoblast differentiation, proliferation and survival. Short-term studies of antibody mediated inhibition of sclerostin in animals and postmenopausal women have consistently shown stimulation of bone formation and reduced or unaltered bone resorption. Clinical studies in postmenopausal women have shown increases in bone mass. If these two new treatments demonstrate anti-fracture efficacy at the same level or better as the best of the currently approved treatments, they will become valuable tools for improving the treatment of osteoporosis.
목차
등록된 정보가 없습니다.
참고문헌 (150)
참고문헌 신청
1987 / Consensus development conference: prophylaxis and treatment of osteoporosis / Br Med J 295:914~915
1994 / Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group / World Health Organ Tech Rep Ser 843:1~129
Strom O / 2011 / Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European federation of pharmaceutical industry associations (EFPIA) / Arch Osteoporos 6:59~155
Johnell O / 2005 / Predictive value of BMD for hip and other fractures / J Bone Miner Res 20:1185~1194
Stone KL / 2003 / BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures / J Bone Miner Res 18:1947~1954
1994 / Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group / World Health Organ Tech Rep Ser 843:1~129
Strom O / 2011 / Osteoporosis: burden, health care provision and opportunities in the EU: a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European federation of pharmaceutical industry associations (EFPIA) / Arch Osteoporos 6:59~155
Johnell O / 2005 / Predictive value of BMD for hip and other fractures / J Bone Miner Res 20:1185~1194
Stone KL / 2003 / BMD at multiple sites and risk of fracture of multiple types: long-term results from the study of osteoporotic fractures / J Bone Miner Res 18:1947~1954
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
New Antiresorptive Therapies for Postmenopausal Osteoporosis
대한폐경학회지
2015 .01
-
골다공증의 약물치료: 2022 update
대한의사협회지
2022 .04
-
Emerging Therapies for Osteoporosis
Endocrinology and Metabolism
2015 .01
-
Biological characteristics of osteoporosis drugs: the effect of osteoblast–osteoclast coupling
International Journal of Oral Biology
2019 .01
-
Treatment of Osteoporosis: Unmet Needs and Emerging Solutions
대한골대사학회지
2018 .01
-
Romosozumab for the treatment of osteoporosis
Osteoporosis and Sarcopenia
2018 .01
-
Up-to-Date Knowledge on Osteoporosis Treatment Selection in Postmenopausal Women
대한폐경학회지
2022 .12
-
The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis
Asian Spine Journal
2015 .01
-
Nonsurgical Treatment Strategies after Osteoporotic Hip Fractures
Hip and Pelvis
2015 .01
-
New Biological Markers of Bone Metabolism in Osteoporosis Treatment
Endocrinology and Metabolism
2016 .01
-
Environmental Air Pollution and the Risk of Osteoporosis and Bone Fractures
예방의학회지
2018 .01
-
Environmental Air Pollution and the Risk of Osteoporosis and Bone Fractures
예방의학회지
2018 .01
-
Operationalizing Treat-to-Target for Osteoporosis
Endocrinology and Metabolism
2021 .01
-
남성 골다공증의 위험 요인에 대한 최신 지견과 공중보건학적 중재 전략
보건교육건강증진학회지
2023 .06
-
RANKL 억제제의 최신 업데이트
대한내과학회지
2018 .01
-
Best Laboratory Screening in Diagnosing Secondary Osteoporosis and Fracture Risk Assessment Tool and the National Osteoporosis Guideline Group Performance in Determining Clinical Risk: A Cross-Sectional Evaluation of the Bone Health in Postmenopausal Brazilian Women
대한골대사학회지
2023 .02
-
Medical treatment of severe osteoporosis including new concept of advanced severe osteoporosis
Osteoporosis and Sarcopenia
2016 .01
-
Does Discontinuing Teriparatide Treatment and Replacing It with Bisphosphonate Maintain the Volume of the Bone Fusion Mass after Lumbar Posterolateral Fusion in Women with Postmenopausal Osteoporosis?
Asian Spine Journal
2017 .01
-
The Association between Urine Albumin to Creatinine Ratio and Osteoporosis in Postmenopausal Women with Type 2 Diabetes
대한골대사학회지
2016 .01
-
Positive Effects of Biologics on Osteoporosis in Rheumatoid Arthritis
대한류마티스학회지
2023 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0